The Department of Pharmacy and the Department of Hematology at Peking University Third Hospital Jointly Develop a Chinese Expert Consensus on the Evidence-Based Safety Management of BTK Inhibitors

Author: Song Zaiwei, Jiang Dan

https://www.puh3.net.cn/info/1971/130011.htm

Recently, the "Evidence-based Expert Consensus on Clinical Management of Safety of Bruton’s Tyrosine Kinase Inhibitors (2024)," initiated by Professor Zhao Rongsheng from the Department of Pharmacy and Professor Jing Hongmei from the Department of Hematology at Peking University Third Hospital, was published in the Chinese Journal of Cancer Research. The publication of this consensus promotes a comprehensive, multi-dimensional, and standardized safety management process for BTK inhibitors, including precise risk assessment before treatment, precise risk monitoring during treatment, and precise post-treatment care, thereby enhancing the safety of BTK inhibitor use.

Figure 1 Screenshot of Expert Consensus